Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma

Aim:  It has been well established that the aberrant activation of the Wnt/β‐catenin signal correlates to endometrial endometrioid adenocarcinoma (EEC). As an effector of the Wnt/β‐catenin mediated antiapoptotic signal, the role of Wnt‐induced secreted protein‐1 (WISP‐1) in EEC still remains unclear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of obstetrics and gynaecology research 2011-06, Vol.37 (6), p.606-612
Hauptverfasser: Tang, Qionglan, Jiang, Xuefeng, Li, Haigang, Lin, Zhongqiu, Zhou, Xiaodong, Luo, Xin, Liu, Li, Chen, Gengbiao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim:  It has been well established that the aberrant activation of the Wnt/β‐catenin signal correlates to endometrial endometrioid adenocarcinoma (EEC). As an effector of the Wnt/β‐catenin mediated antiapoptotic signal, the role of Wnt‐induced secreted protein‐1 (WISP‐1) in EEC still remains unclear. Methods:  We used immunohistochemistry and quantitative real‐time RT‐PCR to examine the expression of WISP‐1, the estrogen receptor (ER) and progesterone receptor (PR) in 86 cases of EEC, with 20 cases of endometrial hyperplasia, 20 of proliferative endometrium and 20 of secretory endometrium used as the control group. We also correlated the expression of WISP‐1 with various clinicopathologic factors and prognostic values in patients with EEC. Results:  A high expression of WISP‐1 was observed in 26 of the 86 cases of EEC (30.2%). The expression rate of WISP‐1 in EEC was significantly higher than that in secretory endometrium (P 
ISSN:1341-8076
1447-0756
DOI:10.1111/j.1447-0756.2011.01631.x